-
Assessing the Socioeconomic Value of Ocrelizumab Subcutaneous for Treating Relapsing Multiple Sclerosis in the Evolving Treatment Landscape in the United Kingdom
Sep 9, 2025, 16:22 PM -
Increased Adherence to Biologic Therapies Leads to Lower All-Cause and Asthma-Related (HCRU) Costs in Severe Asthma
Sep 9, 2025, 16:22 PM -
Live Attenuated Influenza Vaccination (LAIV) for the Prevention of Influenza Illness in Sweden: A Cost-Effectiveness Analysis
Sep 9, 2025, 16:22 PM -
Evolution of MRD in Hemato-Oncology Clinical Development
Sep 9, 2025, 16:22 PM -
Analytical Modeling in Economic Evaluations of Obesity Interventions to Inform Health Policy: A Narrative Review
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness of Coblation Intracapsular Tonsillectomy in the Management of Sleep-Disordered Breathing and Recurrent Tonsillitis: A Brazilian Perspective
Sep 9, 2025, 16:22 PM -
Cost-Consequence and Clinical Impact of NGS Testing in Advanced Lung Adenocarcinoma: Real-World Evidence From a Portuguese Public Hospital
Sep 9, 2025, 16:22 PM -
Impact of Budesonide-Glycopyrronium Formoterol Initiation on Healthcare Resource Utilization and Carbon Emissions in Patients With COPD in Spain: Insights From the ORESTES Study
Sep 9, 2025, 16:22 PM -
Evolution of Pharmaceutical Pricing and Reimbursement Agreements in Spain Over the Last 10 Years: Towards an Outcomes-Based Approach
Sep 9, 2025, 16:22 PM -
Development and Assessment of a Portability Strategy for Computable Operational Definitions
Sep 9, 2025, 16:22 PM -
Revisiting Rarity: Would Yesterday’s NICE Highly Specialized Technologies Still Qualify Today?
Sep 9, 2025, 16:22 PM -
Artificial Intelligence in Pharmaceutical Payer Decision Making—Assessing Current Use, Strategic Intent, and Infrastructure Readiness
Sep 9, 2025, 16:22 PM -
Economic and Social Burden of Pulmonary Hypertension in Italy
Sep 9, 2025, 16:22 PM -
How Societal Is Sweden? A Study of Inclusion of Societal Costs in Swedish Reimbursement Decisions
Sep 9, 2025, 16:22 PM -
Reconsidering Generic Utilities: Implications for Equitable Health Technology Appraisal
Sep 9, 2025, 16:22 PM -
Factors Associated With the Highest Costs Among US Adults With Primary Biliary Cholangitis
Sep 9, 2025, 16:22 PM -
Economics of Improved Time in Range in Type 1 Diabetes Management in Italy, Spain, Greece, and Israel
Sep 9, 2025, 16:22 PM -
Systematic Review of Value Assessment Frameworks for Digital Health Interventions: Toward a Multidimensional Evaluation Approach
Sep 9, 2025, 16:22 PM -
Too Advanced for STA, Too Common for HST? Navigating NICE Appraisals of Gene Therapies
Sep 9, 2025, 16:22 PM -
From Participation to Partnership: Advancing Patient-Centric Inclusive and Equitable Evidence Generation in HEOR
Sep 9, 2025, 16:22 PM
